Phase I Pharmacokinetics Study of Drug «COVID-globulin» (Specific Human Immunoglobulin Against COVID-19)-Reference-Cited by-同舟云学术

Phase I Pharmacokinetics Study of Drug «COVID-globulin» (Specific Human Immunoglobulin Against COVID-19)

Published:2022-05-30 Issue:2 Volume:11 Page:180-186
ISSN:2658-5049
Container-title:Drug development & registration
language:
Short-container-title:Razrabotka i registraciâ lekarstvennyh sredstv

Author:

Smolyanova T. I.¹^ORCID,Bagaeva N. S.²^ORCID,Kolganova M. A.²^ORCID,Shohin I. E.²^ORCID,Nikolaeva A. M.³^ORCID,Vyaznikova T. V.³^ORCID,Pankratova A. A.³^ORCID,Bykova E. A.³^ORCID

Affiliation:

1. JSC "Nacimbio"

2. LLC "CPHA"

3. JSC "NPO "Microgen"

Publisher

Center of Pharmaceutical Analytics Ltd

Subject

Drug Discovery,Pharmaceutical Science

Reference10 articles.

1. Nikiforov V. V., Suranova T. G., Chernobrovkina T. Yu., Yankovskaya Y. D., Burova S. V. New Coronavirus Infection (Covid-19): Clinical and Epidemiological Aspects. The Russian Archives of Internal Medicine. 2020;10(2):87–93. (In Russ.) DOI: 10.20514/2226-6704-2020-10-2-87-93.

2. Baklaushev V. P., Kulemzin S. V., Gorchakov A. A., Ysubalieva G. M., Lesnyak V. N., Sotnikova A. G. COVID-19. Etiology, Pathogenesis, Diagnosis and Treatment. Journal of Clinical Practice. 2020;11(1):7–20. (In Russ.) DOI: 10.17816/clinpract26339.

3. Jiang S., Du L., Shi Z. An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies. Emerging Microbes & Infections. 2020;9(1):275–277. DOI: 10.1080/22221751.2020.1723441.

4. Corti D., Misasi J., Mulangu S., Stanley D. A., Kanekiyo M., Wollen S., Ploquin A., Doria-Rose N. A., Staupe R. P., Bailey M., Shi W., Choe M., Marcus H., Thompson E. A., Cagigi A., Silacci C., Fernandez-Rodriguez B., Perez L., Sallusto F., Vanzetta F., Agatic G., Cameroni E., Kisalu N., Gordon I., Ledgerwood J. E., Mascola J. R., Graham B. S., Muyembe-Tamfun J. J., Trefry J. C., Lanzavecchia A., Sullivan N. J. Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science. 2016;351(6279):1339–1342. DOI: 10.1126/science.aad5224.

5. Sapparapu G., Fernandez E., Kose N., Cao B., Fox J. M., Bombardi R. G., Zhao H., Nelson C. A., Bryan A. I., Barnes T., Davidson E., Mysorekar I. U., Fremont D. H., Doranz B. J., Diamond M. S., Crowe J. E. Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice. Nature. 2016;540(7633):443–447. DOI: 10.1038/nature20564.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The physical, social, and mental conditions of machine learning in student health evaluation;Journal of Computer Assisted Learning;2024-05-14

2. The use of immunoglobulins and monoclonal antibodies against COVID-19;Problems of Virology;2024-05-06

3. Evaluation of the effectiveness of immunoglobulins in treatment of infectious diseases;Vrach;2024-03-01

4. Phase I Pharmacokinetics Study of Oral Administration of Esperavir® (INN: Molnupiravir) (LLC "PROMOMED RUS", Russia);Drug development & registration;2024-02-19

5. Phase I Pharmacokinetics Study of Drug for Infusion «Areplivir» (INN: Favipiravir) (LLC "PROMOMED RUS", Russia);Drug development & registration;2023-05-28